This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. After many months (or years) of grinding, your science seems to be working, the market is responding to your story,

With the NASDAQ sector indices still up 17% for the year, and IPOs continuing at a robust pace, the biotech investing climate continues to be an exciting one. Amidst these rising stock prices, or at least perceptions, I frequently get

Biotech has been on a tear over the past few years supported by a combination of scientific advances, great IPO and M&A exit environments, and robust capital markets for fundraising. Watching the public indices gives a good indicator of broader

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. I had an interesting discussion with a veteran of a rapidly growing biotech. He’d been at his company at the

This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. We all have stuff lying around our homes or offices that we have no further use for but that might be

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In a previous post I was extolling the virtues of leading a private company. Specifically, the freedom of being able

Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in biotech companies in 2Q 2015, bringing the year

This blog was written by Bill Marshall, co-founder and CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. microRNAs are an exciting new class of gene regulatory molecules that act on systems biology, and their modulation

The stock market has been a wild ride of late – big moves up and down, NYSE getting halted, Grexit, China – lots of reasons for added skittishness. The VIX index, which measures the volatility of the S&P500, has gone

External models of R&D innovation are the rage in Pharma today, as they should be – the future of our industry depends on a great deal more rather than less collaboration. In a very healthy way, lots of experiments are

Figuring out what disease areas are attracting the most venture funding and deal-related capital in startup and emerging biotech has historically been quite challenging as few if any datasets track it comprehensively. But late last week, on the eve of

This blog was written by Jeff Hatfield, CEO of Pennsylvania-based Vitae Pharmaceuticals, as part of the “From the Trenches” feature of LifeSciVC. Next week, BIO returns to Philadelphia for its massive annual convention, bringing together from around the world more than